2076975 2077203
최종편집 2022-12-03 18:52 (토)
COVID-19 impact on the big pharma withered, Q2 growth reduced
상태바
COVID-19 impact on the big pharma withered, Q2 growth reduced
  • Hyeokgi Lee, Newsmp
  • 승인 2022.08.12 19:46
  • 댓글 0
이 기사를 공유합니다

Moderna, single-digit growth in Q2… ViatrisㆍBiogen contracted
Pfizer 46.8%ㆍAZ 31.0%↑… Growth shrinks from Q1

[Newsmp] In the second quarter, the growth of global big pharma has shrunk as the Omicron variant peaked.

As a result of Newsmp compiled the second-quarter reports of major global big

Companies with COVID-19 vaccines and treatments continued to grow, but they also saw their growth shrink in the second quarter.

In particular, Moderna, which recorded a growth rate of more than 200% in the first quarter, has reduced a single digit (9.1%) in the second quarter. This brought the increase in cumulative sales in the semi-annual period also declined to 71.9%.

Pfizer also posted more than 70% growth in the first quarter but decreased to 46.8% in the second quarter. Nevertheless, the cumulative sales growth in the semi-annual period was close to 60%.

Pfizer’s sales amounted to about KRW 36 trillion (based on the exchange rate on the 8th), surpassing Johnson & Johnson, which even owns medical devices.

AstraZeneca also recorded a growth rate of more than 50% in the first quarter, but the second quarter’s growth has been reduced to 31.0%.

Although MSD and GSK's growth decreased from the first quarter, they maintained double-digit growth, and Novo Nordisk and Sanofi, which recorded double-digit growth with them, expanded their growth a little more.

In addition, BMS, Gilead Sciences, Roche, and Amgen remained at around 1% growth, and AbbVie’s growth did not exceed 5%.

, most of them were estimated to have a lower second-quarter growth compared to the cumulative sales growth in the semi-annual period. This means that the growth has decreased from the first quarter.

In particular, Viatris and Biogen saw their growth drop, Lilly, Organon, and Novartis, and Novartis turned to negative growth in the second quarter, reducing cumulative sales from the same period last year.

quarter. Nevertheless, the cumulative sales growth in the semi-annual period was close to 60%.

Pfizer’s sales amounted to about KRW 36 trillion (based on the exchange rate on the 8th), surpassing Johnson & Johnson, which even owns medical devices.

AstraZeneca also recorded a growth rate of more than 50% in the first quarter, but the second quarter’s growth has been reduced to 31.0%.

Although MSD and GSK's growth decreased from the first quarter, they maintained double-digit growth, and Novo Nordisk and Sanofi, which recorded double-digit growth with them, expanded their growth a little more.

In addition, BMS, Gilead Sciences, Roche, and Amgen remained at around 1% growth, and AbbVie’s growth did not exceed 5%.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.